Alexandros Makriyannis (born September 9, 1939) is an American biochemist and professor of chemistry and chemical biology in the department of medicinal chemistry at Northeastern University in Boston, Massachusetts, where he directs the Center for Drug Discovery and holds the George Behrakis Chair of Pharmaceutical Biotechnology.
[1] His research has focused on the biochemical basis of the endocannabinoid system and on the development of synthetic cannabinoids.
[7] These studies have informed the development by Makriyannis and his collaborators of synthetic compounds with a view to their use as cannabinergic probes or as medications in drug addiction[8] and in obesity and metabolic disorders.
Vemuri 2014 Novel urea and carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and their uses thereof” – A. Makriyannis, V.G.
Alapafuja 2014 “N·Acylethanolamlne Hydrolyzing Acid Amldase (NAAA) Inhibitors and Their Use Thereof” – A. Makriyannis, M. Malamas, K.V Subramanian, K. Whitten, N. Zvonok, J.M West, S. Pavlopoulos 2017 “Carbarnates ABHD6 and dual ABHD6/MGL Inhibitors and their use thereof”- A. Makriyannis, M. Malamas, M. Lamani, S.I Farah Makriyannis has founded two biotechnology startups in Burlington, MA dedicated to bringing new and innovative drugs to the market place for human diseases that can be modulated by the endocannabinoid system: